Abstract
Staphylococcus aureus is a leading causative agent in sepsis, endocarditis, and pneumonia. An emerging concept is that prognosis worsens when the infecting S. aureus strain has the capacity to not only colonize tissue as an extracellular pathogen, but to invade host cells and establish intracellular bacterial populations. In previous work, we identified host CDC42 as a central regulator of endothelial cell invasion by S. aureus. In the current work, we report that ML 141, a first-in-class CDC42 inhibitor, decreases invasion and resultant pathogenesis in a dose-dependent and reversible manner. Inhibition was found to be due in part to decreased remodeling of actin that potentially drives endocytic uptake of bacteria/fibronectin/integrin complexes. ML 141 decreased binding to fibronectin at these complexes, thereby limiting a key pathogenic mechanism used by S. aureus to invade. Structural analogs of ML 141 were synthesized (designated as the RSM series) and a subset identified that inhibit invasion through non-cytotoxic and non-bactericidal mechanisms. Our results support the development of adjunctive therapeutics targeting host CDC42 for mitigating invasive infection at the level of the host.
Keywords: CDC42, fibronectin, ML 141, MRSA, MSSA, pyrazolines, sepsis.
Current Pharmaceutical Biotechnology
Title:Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Volume: 15 Issue: 8
Author(s): Diana Cordero, Christopher R. Fullenkamp, Rachel R. Pelly, Katie M. Reed, Lindy M. Caffo, Ashley N. Zahrt, Micaleah Newman, Sarah Komanapalli, Evan M. Niemeier, Derron L. Bishop, Heather A. Bruns, Mark K. Haynes, Larry A. Sklar, Robert E. Sammelson and Susan A. McDowell
Affiliation:
Keywords: CDC42, fibronectin, ML 141, MRSA, MSSA, pyrazolines, sepsis.
Abstract: Staphylococcus aureus is a leading causative agent in sepsis, endocarditis, and pneumonia. An emerging concept is that prognosis worsens when the infecting S. aureus strain has the capacity to not only colonize tissue as an extracellular pathogen, but to invade host cells and establish intracellular bacterial populations. In previous work, we identified host CDC42 as a central regulator of endothelial cell invasion by S. aureus. In the current work, we report that ML 141, a first-in-class CDC42 inhibitor, decreases invasion and resultant pathogenesis in a dose-dependent and reversible manner. Inhibition was found to be due in part to decreased remodeling of actin that potentially drives endocytic uptake of bacteria/fibronectin/integrin complexes. ML 141 decreased binding to fibronectin at these complexes, thereby limiting a key pathogenic mechanism used by S. aureus to invade. Structural analogs of ML 141 were synthesized (designated as the RSM series) and a subset identified that inhibit invasion through non-cytotoxic and non-bactericidal mechanisms. Our results support the development of adjunctive therapeutics targeting host CDC42 for mitigating invasive infection at the level of the host.
Export Options
About this article
Cite this article as:
Cordero Diana, Fullenkamp R. Christopher, Pelly R. Rachel, Reed M. Katie, Caffo M. Lindy, Zahrt N. Ashley, Newman Micaleah, Komanapalli Sarah, Niemeier M. Evan, Bishop L. Derron, Bruns A. Heather, Haynes K. Mark, Sklar A. Larry, Sammelson E. Robert and McDowell A. Susan, Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus, Current Pharmaceutical Biotechnology 2014; 15 (8) . https://dx.doi.org/10.2174/1389201015666140909124310
DOI https://dx.doi.org/10.2174/1389201015666140909124310 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Oral Colonization by Nosocomial Pathogens During Hospitalization in Intensive Care Unit and Prevention Strategies
Recent Patents on Anti-Infective Drug Discovery Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Multiple Roles of Biosurfactants in Biofilms
Current Pharmaceutical Design The Management of the Infected Diabetic Foot
Current Diabetes Reviews New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Outpatient Treatment of Hemorrhoidal Disease: The Alternative Way to Treat Hemorrhoidal Disease in a Simple, Safe and Effective Manner
Reviews on Recent Clinical Trials The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Receptor Binding Ligands to Image Infection
Current Pharmaceutical Design The Role of the Coagulase-negative Staphylococci (CoNS) in Infective Endocarditis; A Narrative Review from 2000 to 2020
Current Pharmaceutical Biotechnology The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Systemic Inflammatory Response as a Risk and Prognosis Factor in Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets High-Level Aminoglycoside Resistance in Enterococcus Faecalis and Enterococcus Faecium; as a Serious Threat in Hospitals
Infectious Disorders - Drug Targets Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Waste Material of Propolis as a Film Forming Agent Intended to Modify the Metronidazole Release: Preparation and Characterization
Current Drug Delivery Prevalence of Nasal Colonization with Staphylococcus aureus in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Optimal antibiotic dosage for chronic kidney disease patient: a pharmacological manual for oral clinicians
Recent Patents on Anti-Infective Drug Discovery